<?xml version="1.0" encoding="UTF-8"?>
<p>For the primary efficacy endpoint, NEPA demonstrated non-inferiority to APR/GRAN with overall CR rates of 73.8% and 72.4%, respectively (95% CI: âˆ’4.5%, 7.5%) (Figure 
 <xref ref-type="fig" rid="mdx698-F1">1</xref>). 
</p>
